Adage Capital Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Adage Capital Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,000	Closed	-$3.32M	–	865
2024 Q4	$3.32M	Buy	65,000 +25,000	+63%	+$1.4M	0.01%	753
2024 Q3	$2.04M	Sell	40,000 -161,048	-80%	-$8.31M	﹤0.01%	782
2024 Q2	$9M	Sell	201,048 -431,085	-68%	-$19.9M	0.02%	623
2024 Q1	$29.6M	Buy	+632,133	New	+$24.7M	0.06%	359
2023 Q3	–	Sell	-225,000	Closed	-$4.05M	–	883
2023 Q2	$4.05M	Buy	+225,000	New	+$4.49M	0.01%	692
2019 Q3	–	Sell	-490,000	Closed	-$12.3M	–	725
2019 Q2	$12.3M	Buy	490,000 +200,000	+69%	+$4.95M	0.03%	493
2019 Q1	$6.6M	Hold	290,000	–	–	0.02%	581
2018 Q4	$8.7M	Buy	290,000 +90,000	+45%	+$2.53M	0.02%	534
2018 Q3	$5.73M	Buy	+200,000	New	+$5.94M	0.01%	624

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's CRNX Position: Q1 2025 in Review

Adage Capital Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 65,000 shares — an estimated $3.32M sold.

Adage Capital Partners first reported a position in CRNX in Q3 2018 and held it in 9 quarters. The position peaked at $29.6M in Q1 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

Adage Capital Partners reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Adage Capital Partners sold 65,000 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $3.32M.
Adage Capital Partners first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 9 quarters.
Adage Capital Partners's Crinetics Pharmaceuticals position peaked at $29.6M in Q1 2024.
227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.